Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) announced on Friday that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It follows the successful completion of the ADHERE clinical trial, which demonstrated VYVDURA's efficacy and safety in treating CIDP.
VYVDURA is approved for once-weekly subcutaneous self-administration at home, offering a convenient treatment option for patients.
Earlier this year VYVDURA was approved for the treatment of generalised myasthenia gravis (gMG) in Japan.
CIDP is a rare and debilitating neurological disorder with limited treatment options.
VYVDURA is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP in Japan.
Eli Lilly's Omvoh receives US FDA approval
Incyte and Syndax receive US FDA approval for Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vials
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
PacBio and Intus Bio launch GutID, first at-home microbiome test powered by HiFi sequencing
Veralox Therapeutics agrees Nudge Therapeutics acquisition
Xentria announces operational expansion of multiple clinical trials in 2025
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy